Research Analysts Issue Forecasts for OptimizeRx Q1 Earnings

OptimizeRx Co. (NASDAQ:OPRX) – Analysts at Roth Capital issued their Q1 2026 EPS estimates for shares of OptimizeRx in a report issued on Wednesday, March 12th. Roth Capital analyst R. Baldry anticipates that the company will post earnings of ($0.19) per share for the quarter. The consensus estimate for OptimizeRx’s current full-year earnings is ($0.33) per share. Roth Capital also issued estimates for OptimizeRx’s Q2 2026 earnings at ($0.16) EPS, Q3 2026 earnings at ($0.05) EPS and Q4 2026 earnings at $0.44 EPS.

OPRX has been the subject of several other research reports. B. Riley upgraded shares of OptimizeRx to a “strong-buy” rating in a report on Wednesday, March 12th. Royal Bank of Canada reiterated a “sector perform” rating and set a $6.00 target price (down from $7.00) on shares of OptimizeRx in a research report on Wednesday, January 8th. JMP Securities restated a “market outperform” rating and set a $8.00 target price on shares of OptimizeRx in a research report on Thursday, February 6th. Stephens assumed coverage on OptimizeRx in a report on Friday, December 20th. They issued an “equal weight” rating and a $5.50 target price on the stock. Finally, Lake Street Capital restated a “buy” rating and issued a $11.00 price target on shares of OptimizeRx in a report on Tuesday, December 24th. Three research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, OptimizeRx presently has an average rating of “Moderate Buy” and a consensus price target of $9.06.

OptimizeRx Price Performance

OptimizeRx stock opened at $7.77 on Monday. The company’s 50 day simple moving average is $5.53 and its 200-day simple moving average is $5.90. OptimizeRx has a 1 year low of $3.78 and a 1 year high of $14.13. The company has a market capitalization of $143.13 million, a price-to-earnings ratio of -5.84 and a beta of 1.31. The company has a debt-to-equity ratio of 0.29, a quick ratio of 3.23 and a current ratio of 3.23.

Hedge Funds Weigh In On OptimizeRx

A number of institutional investors and hedge funds have recently added to or reduced their stakes in OPRX. Barclays PLC boosted its stake in shares of OptimizeRx by 358.5% in the 3rd quarter. Barclays PLC now owns 26,934 shares of the company’s stock valued at $208,000 after purchasing an additional 21,060 shares during the last quarter. Janney Montgomery Scott LLC acquired a new stake in OptimizeRx in the 3rd quarter valued at $810,000. BNP Paribas Financial Markets grew its holdings in shares of OptimizeRx by 189.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company’s stock valued at $28,000 after acquiring an additional 2,414 shares in the last quarter. Quest Partners LLC raised its holdings in OptimizeRx by 15,965.6% during the third quarter. Quest Partners LLC now owns 9,800 shares of the company’s stock worth $76,000 after acquiring an additional 9,739 shares in the last quarter. Finally, SG Americas Securities LLC bought a new position in OptimizeRx in the fourth quarter valued at approximately $51,000. 76.47% of the stock is currently owned by institutional investors and hedge funds.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.